Recent News

• 08.05.2026 - Coherus Oncology Reports Second Quarter 2026 Financial Results and Provides Business Update
• 07.22.2026 - Coherus Oncology to Report Second Quarter 2026 Financial Results on August 5, 2026
• 06.23.2026 - Coherus and Zumutor Biologics Announce Clinical Collaboration to Evaluate ZM008 in Combination with LOQTORZI® (toripalimab-tpzi)
• 02.13.2026 - Coherus Oncology, Inc. Announces Pricing of Public Offering of Common Stock
• 02.12.2026 - Coherus Oncology, Inc. Announces Proposed Public Offering of Common Stock
• 01.06.2026 - Coherus Management to Present at the 44th Annual J.P. Morgan Healthcare Conference
• 01.05.2026 - Coherus Oncology Announces Publication in Molecular Cancer Therapeutics Highlighting the Strong Pharmacology of Investigational CCR8 Antibody Tagmokitug (CHS-114)
• 12.08.2025 - Coherus Announces Six-Year JUPITER-02 Follow-up Results Showing LOQTORZI® plus Chemotherapy Nearly Doubles Median Overall Survival in Nasopharyngeal Carcinoma
• 11.07.2025 - Coherus Oncology Presents at SITC Clinical Multiomic Biomarker Data for CHS-114, a Highly Selective anti-CCR8 Cytolytic Antibody
• 11.06.2025 - Coherus Oncology Reports Third Quarter 2025 Financial Results and Provides Business Update

Recent Filings

• 08.05.2026 - S-8 Securities to be offered to employees in employee benefit plans
• 08.05.2026 - 10-Q Quarterly report [Sections 13 or 15(d)]
• 08.05.2026 - 8-K Current report
• 08.05.2026 - EX-99.1 EX-99.1
• 07.27.2026 - SCHEDULE 13G Statement of Beneficial Ownership by Certain Investors
• 06.15.2026 - 8-K Current report
• 06.09.2026 - 4 Statement of changes in beneficial ownership of securities
• 06.09.2026 - 4 Statement of changes in beneficial ownership of securities
• 06.09.2026 - 4 Statement of changes in beneficial ownership of securities
• 06.09.2026 - 4 Statement of changes in beneficial ownership of securities